This episode of The Motley Fool's Market Checkup drills down on the day's hottest headlines and takes a look at two favorite health care-focused dividend stocks. Market Checkup gives a full examination of the recent regulatory action around a new blood cancer drug, a European orphan drug approval, and why a Big Pharma shockingly stopped the FDA from reviewing its newest diabetes drug.
In this video, health-care analysts David Williamson and Max Macaluso discuss Why Amgen's small but increasing dividend shouldn't be overlooked. Watch and find out about how Amgen's growth potential -- with its recent cancer-focused acquisition, next-gen cholesterol fighter, and biosimilar initiative -- combine with strong cash flow generation and a low payout ratio to form a dividend stock for the long term.
Follow David on Twitter: @MotleyDavid.
David Williamson owns shares of Pfizer and Johnson & Johnson. Follow David on Twitter: @MotleyDavid. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends and owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
What to Expect From Amgen, Inc. in 2018
California's biggest biotech is poised for an eventful 2018. Here's what you need to look out for.
Will 2018 Be Amgen Inc.'s Best Year Yet?
It would take jumping some really high hurdles.
5 Things Amgen's CEO Just Said That Investors Need to Know
Bob Bradway focused on acquisitions, growth, and more at the J.P. Morgan Healthcare Conference.